Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819653 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49353 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7647781 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7644168 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL2917831 | 1.00 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1679057 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1678725 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1679055 | 0.96 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49819 | 0.96 | EPHX1 (0.44) | EPHX1HIF1AALDH1A1SIGMAR1KMT2A | |
| SCHEMBL1678970 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3395583-B1 | HEAT-SENSITIVE RECORDING MATERIAL | NIPPON KAYAKU KK (JP) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11802208-B2 | Stilbene-based compound or salt thereof, and polarizing film, polarizing plate, and display device | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| EP-3689891-B1 | COBALT COMPLEX, PRODUCTION METHOD THEREFOR, AND CATALYST FOR HYDROSILYLATION REACTION | UNIV KYUSHU NAT UNIV CORP (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-20230019461-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-3998502-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | Nippon Kayaku Kabushiki Kaisha (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-3183757-B1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | CLAP CO LTD (KR) | 2022-05-04 | — | — | EP | disclosed |
| EP-3224246-B1 | 4-OXOQUINOLINE COMPOUNDS | BASF SE (DE) | 2022-01-12 | — | — | EP | disclosed |
| US-10780724-B2 | Heat-sensitive recording material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-09-22 | — | — | US | disclosed |
| WO-1997032887-A1 | OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| US-5498609-A | Benzoazepinyl compounds as oxytocin and vasopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0612319-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
| WO-1994004525-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-03 | — | — | WO | disclosed |
| EP-0167817-B1 | 8-Alkylthio-2-piperazino-pyrimido[5,4-d]pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1989-09-20 | — | — | EP | disclosed |
| US-4714698-A | ANTITUMOR, ANTICOAGULANT | DR. KARL THOMAE GMBH (DE) | 1987-12-22 | — | — | US | disclosed |
| EP-0167817-A1 | 8-Alkylthio-2-piperazino-pyrimido[5,4-d]pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1986-01-15 | — | — | EP | disclosed |
| EP-0055444-B1 | TRISUBSTITUTED PYRIMIDO(5,4-D)PYRIMIDINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-03-20 | — | — | EP | disclosed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | disclosed |
| EP-0055444-A2 | Trisubstituted pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780724-B2 | Heat-sensitive recording material | KCNH2, KCNH3, TRPA1 | EPHX1 3769/4885HIF1A 1886/4885ALDH1A1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.